Polycythemia Vera Market to Advance at Moderate CAGR During the Forecast Period (2023-2032) - Estimates DelveInsight | Protagonist Therapeutics, Imago BioSciences, Italfarmaco, Silence Therapeutics, Ionis Pharma, Perseus Proteomics, Sanofi, Roche

The Polycythemia Vera market is witnessing a transformative evolution with the introduction of novel therapies targeting the underlying molecular mechanisms of the disease. Advancements in understanding the genetic and molecular pathways involved in Polycythemia Vera are driving the development of targeted treatments with the potential to improve disease management and patient outcomes. Furthermore, there's a growing emphasis on personalized medicine approaches, aiming to tailor treatments based on individual patient characteristics, paving the way for more effective and precise interventions in Polycythemia Vera management.

DelveInsight's "Polycythemia Vera Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Polycythemia Vera Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Polycythemia Vera therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Polycythemia Vera treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Polycythemia Vera: An Overview
Polycythemia Vera (PV) is characterized by an increased number of red blood cells in the bloodstream (erythrocytosis); affected people may also have excess white blood cells and platelets. Most cases of Polycythemia Vera are not inherited and are acquired during a person's lifetime. Mutation in the JAK2 kinase is responsible for Polycythemia Vera. Most Polycythemia Vera cases are associated with somatic genetic changes, which pass on genetic information to offspring. Polycythemia Vera is usually diagnosed at the average age of people 60-65 years. It is uncommon in people under the age of 40. Polycythemia Vera develops more often in men than in women.

In the early stages, there are not any specific signs and symptoms. When too many RBCs and platelets build up in the blood, symptoms start to appear, which may cause a problem. The symptoms are not noticeable due to an increased cell count but can predict a higher risk of clot formation.

Headache, dizziness, fatigue, blurred vision or blind spots, shortness of breath, itchy skin, spleen enlargement (Splenomegaly), blood clots, heavy bleeding, and others are the symptoms of Polycythemia Vera. The most precarious symptom of Polycythemia Vera is the chance for a thrombotic event that can cause a heart attack or stroke. There is also a small chance that Polycythemia Vera could cause an individual to develop leukemia.

Polycythemia Vera Market Key Facts
• The total market size of Polycythemia Vera in the 7MM is approximately USD 1,800 million in 2022.
• The market size in the 7MM will increase at a CAGR of 14% due to increasing awareness of the disease and the launch of the emerging therapy
• Among EU4 countries, Germany accounts for the maximum market size in 2022 while Spain occupies the bottom of the ladder in 2022
• The market size of Polycythemia Vera in Japan is USD 100 million in 2022, which is expected to rise during the forecast period (2023-2032)
• The total prevalent cases of Polycythemia Vera in the 7MM comprised of approximately 309,000 cases in 2022 and are projected to increase during the forecasted period
• The total prevalent cases of Polycythemia Vera in the United States were around 179,000 cases in 2022
• The United States contributed to the largest prevalent population of Polycythemia Vera, acquiring ~58% of the 7MM in 2022. Whereas EU4, the UK, and Japan accounted for around 32% and 10% of the total population share, respectively, in 2022
• Among the EU4 countries, Germany accounted for the largest number of Polycythemia Vera cases followed by France, whereas Spain accounted for the lowest cases in 2022
• According to DelveInsight estimates, there were around 72,000 cases of asymptomatic and 107,000 cases of symptomatic Polycythemia Vera in the United States in 2022. The prevalence is projected to increase during the forecasted period
• In Japan, the prevalent Polycythemia Vera cases were around 13,000 in males and 7,000 in females in 2022.

Get a Detailed Overview of the Evolving Polycythemia Vera Market Trends @
https://www.delveinsight.com/report-store/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Polycythemia Vera Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Polycythemia Vera therapies in the market. It also provides a detailed assessment of the Polycythemia Vera market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Polycythemia Vera drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Polycythemia Vera Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Polycythemia Vera Epidemiology
The epidemiology section covers detailed insights into the historical, and current Polycythemia Vera patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Polycythemia Vera Epidemiology Segmented as -
• Total prevalent cases of Polycythemia Vera
• Prevalent population of Polycythemia Vera based on symptoms
• Gender-specific cases of Polycythemia Vera
• Prevalence of Polycythemia Vera by gene mutation
• Prevalence of Polycythemia Vera based on risk
• Age-specific prevalence of Polycythemia Vera

Get Key Insights Into the Evolving Polycythemia Vera Epidemiology Trends @
https://www.delveinsight.com/report-store/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Polycythemia Vera Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polycythemia Vera market or expected to be launched during the study period. The analysis covers the market share by Polycythemia Vera drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Polycythemia Vera Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Polycythemia Vera Market @
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Polycythemia Vera Therapeutics Assessment
The treatment for PV is based on the symptoms and progression, as well as the age of the patients. The goal of treatments for PV is to control symptoms and lower the risk of complications. Treatments like phlebotomy help make the blood thinner when there are too many red blood cells. It is done the same way as donating blood, and drugs like hydroxyurea, interferon alfa, etc., are used. Various other supportive therapies, antihistamines, allopurinol, and aspirin, are also recommended. To date, JAKAFI/JAKAVI and BESREMi are the only two drugs approved for treating Polycythemia Vera by the US FDA.

To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Polycythemia Vera. Currently, Protagonist Therapeutics is leading the therapeutics market with its Polycythemia Vera drug candidates in the most advanced stage of clinical development.

Leading Companies in the Polycythemia Vera Therapeutics Market Include
• Protagonist Therapeutics
• Imago BioSciences
• Italfarmaco
• Silence Therapeutics
• Ionis Pharmaceuticals
• Perseus Proteomics
• Sanofi
• Roche
• Kartos Therapeutics, Inc.
• AOP Orphan Pharmaceuticals AG
And Many Others

Emerging and Marketed Polycythemia Vera Therapies Covered in the Report Include
• PTG-300: Protagonist Therapeutics
• Bomedemstat: Imago BioSciences
• Givinostat: Italfarmaco
• SLN124: Silence Therapeutics
• JAKAFI/JAKAVI (ruxolitinib): Incyte/Novartis
• ESREMi (ropeginterferon alfa-2b): PharmaEssentia/AOP Orphan Pharmaceuticals
And Many More

Learn More About the Emerging Therapies and key Companies in the Polycythemia Vera Therapeutics Market @
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Polycythemia Vera Competitive Intelligence Analysis
4. Polycythemia Vera Market Overview at a Glance
5. Polycythemia Vera Background and Overview
6. Polycythemia Vera Patient Journey
7. Polycythemia Vera Epidemiology and Patient Population
8. Polycythemia Vera Treatment Algorithm, Current Treatment, and Medical Practices
9. Polycythemia Vera Unmet Needs
10. Key Endpoints of Polycythemia Vera Treatment
11. Polycythemia Vera Marketed Products
12. Polycythemia Vera Emerging Therapies
13. Polycythemia Vera Seven Major Market Analysis
14. Attribute Analysis
15. Polycythemia Vera Market Outlook (7 major markets)
16. Polycythemia Vera Access and Reimbursement Overview
17. KOL Views on the Polycythemia Vera Market.
18. Polycythemia Vera Market Drivers
19. Polycythemia Vera Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.